Meridian Bioscience, Inc.
VIVO · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Market Cap | $1,388 | $847 | $733 | $407 |
| - Cash | $81 | $50 | $54 | $62 |
| + Debt | $31 | $66 | $71 | $76 |
| Enterprise Value | $1,337 | $863 | $750 | $421 |
| Revenue | $333 | $318 | $254 | $201 |
| % Growth | 4.8% | 25.3% | 26.2% | – |
| Gross Profit | $188 | $201 | $156 | $118 |
| % Margin | 56.6% | 63.3% | 61.6% | 58.9% |
| EBITDA | $72 | $108 | $75 | $43 |
| % Margin | 21.6% | 33.9% | 29.8% | 21.6% |
| Net Income | $42 | $71 | $46 | $24 |
| % Margin | 12.7% | 22.5% | 18.2% | 12.1% |
| EPS Diluted | 0.96 | 1.62 | 1.07 | 0.57 |
| % Growth | -40.7% | 51.4% | 87.7% | – |
| Operating Cash Flow | $82 | $67 | $48 | $36 |
| Capital Expenditures | -$9 | -$18 | -$3 | -$4 |
| Free Cash Flow | $74 | $49 | $45 | $32 |